Transarterial chemoembolization and Yittrium-90 for liver cancer and other lesions

Jeet Minocha*, Riad Salem, Robert J Lewandowski

*Corresponding author for this work

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Transarterial chemoembolization (TACE) is the recommended treatment of intermediate stage hepatocellular carcinoma (HCC). Radioembolization with yttrium 90 has overcome the shortcomings of external beam radiation in the treatment of liver cancer. TACE and radioembolization have led to encouraging response, survival, and quality of life outcomes, with reduced toxicity profiles. This result has led to the use of these therapies in patients with hepatic metastases, most commonly from colorectal cancer. This article reviews the current state of the practice of TACE and radioembolization and presents recent scientific data that support their role in the treatment of HCC and hepatic metastatic disease.

Original languageEnglish (US)
Pages (from-to)877-890
Number of pages14
JournalClinics in Liver Disease
Volume18
Issue number4
DOIs
StatePublished - Nov 1 2014

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Yttrium
Liver
Therapeutics
Colorectal Neoplasms
Quality of Life
Radiation
Neoplasm Metastasis
Survival

Keywords

  • Chemoembolization
  • Drug-eluting bead (DEB)-TACE
  • Hepatic metastases
  • Hepatocellular carcinoma (HCC)
  • Liver cancer
  • Radioembolization
  • Transarterial chemoembolization (TACE)
  • Yittrium 90 (Y)

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{ffdb07348a90401f8d12be27f56425f1,
title = "Transarterial chemoembolization and Yittrium-90 for liver cancer and other lesions",
abstract = "Transarterial chemoembolization (TACE) is the recommended treatment of intermediate stage hepatocellular carcinoma (HCC). Radioembolization with yttrium 90 has overcome the shortcomings of external beam radiation in the treatment of liver cancer. TACE and radioembolization have led to encouraging response, survival, and quality of life outcomes, with reduced toxicity profiles. This result has led to the use of these therapies in patients with hepatic metastases, most commonly from colorectal cancer. This article reviews the current state of the practice of TACE and radioembolization and presents recent scientific data that support their role in the treatment of HCC and hepatic metastatic disease.",
keywords = "Chemoembolization, Drug-eluting bead (DEB)-TACE, Hepatic metastases, Hepatocellular carcinoma (HCC), Liver cancer, Radioembolization, Transarterial chemoembolization (TACE), Yittrium 90 (Y)",
author = "Jeet Minocha and Riad Salem and Lewandowski, {Robert J}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.cld.2014.07.007",
language = "English (US)",
volume = "18",
pages = "877--890",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Transarterial chemoembolization and Yittrium-90 for liver cancer and other lesions. / Minocha, Jeet; Salem, Riad; Lewandowski, Robert J.

In: Clinics in Liver Disease, Vol. 18, No. 4, 01.11.2014, p. 877-890.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Transarterial chemoembolization and Yittrium-90 for liver cancer and other lesions

AU - Minocha, Jeet

AU - Salem, Riad

AU - Lewandowski, Robert J

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Transarterial chemoembolization (TACE) is the recommended treatment of intermediate stage hepatocellular carcinoma (HCC). Radioembolization with yttrium 90 has overcome the shortcomings of external beam radiation in the treatment of liver cancer. TACE and radioembolization have led to encouraging response, survival, and quality of life outcomes, with reduced toxicity profiles. This result has led to the use of these therapies in patients with hepatic metastases, most commonly from colorectal cancer. This article reviews the current state of the practice of TACE and radioembolization and presents recent scientific data that support their role in the treatment of HCC and hepatic metastatic disease.

AB - Transarterial chemoembolization (TACE) is the recommended treatment of intermediate stage hepatocellular carcinoma (HCC). Radioembolization with yttrium 90 has overcome the shortcomings of external beam radiation in the treatment of liver cancer. TACE and radioembolization have led to encouraging response, survival, and quality of life outcomes, with reduced toxicity profiles. This result has led to the use of these therapies in patients with hepatic metastases, most commonly from colorectal cancer. This article reviews the current state of the practice of TACE and radioembolization and presents recent scientific data that support their role in the treatment of HCC and hepatic metastatic disease.

KW - Chemoembolization

KW - Drug-eluting bead (DEB)-TACE

KW - Hepatic metastases

KW - Hepatocellular carcinoma (HCC)

KW - Liver cancer

KW - Radioembolization

KW - Transarterial chemoembolization (TACE)

KW - Yittrium 90 (Y)

UR - http://www.scopus.com/inward/record.url?scp=84908209304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908209304&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2014.07.007

DO - 10.1016/j.cld.2014.07.007

M3 - Review article

C2 - 25438288

AN - SCOPUS:84908209304

VL - 18

SP - 877

EP - 890

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 4

ER -